ArticleFrontiers in pharmacology2016
Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.6field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 73 citations in OpenAlex.
- Deficits in episodic memory and executive functions in relation to CB1 receptor availability in Parkinson's disease.Journal of Parkinson's disease · 2026Article
- Article
- Article
- Differential effects of cannabidiol on inhibitory avoidance memory reconsolidation and consolidation are associated with distinct hippocampal proBDNF and BDNF signaling profiles.Frontiers in neuroscience · 2026Article
- Preventive beneficial effects of cannabidiol in a reserpine-induced progressive model of parkinsonism.Frontiers in pharmacology · 2025Article
- Role of hippocampal and prefrontal cortical cholinergic transmission in combination therapy valproate and cannabidiol in memory consolidation in rats: involvement of CREB- BDNF signaling pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Article
- Neuroprotective potential of Afzelin: A novel approach for alleviating catalepsy and modulating Bcl-2 expression in Parkinson's disease therapy.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects.Molecules (Basel, Switzerland) · 2024Review
- Assessment of the effects of cannabidiol and a CBD-rich hemp extract inFrontiers in toxicology · 2024Article
- CBD's potential impact on Parkinson's disease: An updated overview.Open medicine (Warsaw, Poland) · 2024Review
- Cannabidiol Recovers Dopaminergic Neuronal Damage Induced by Reserpine or α-synuclein in Caenorhabditis elegans.Neurochemical research · 2023Article
- Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, and Cognitive and Physical Performance.Antioxidants (Basel, Switzerland) · 2023Review
- Beyond Pain Relief: A Review on Cannabidiol Potential in Medical Therapies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Cannabidiol and brain function: current knowledge and future perspectives.Frontiers in pharmacology · 2023Review
- CBD enhances the cognitive score of adolescent rats prenatally exposed to THC and fine-tunes relevant effectors of hippocampal plasticity.Frontiers in pharmacology · 2023Article
- Effects of cannabidiol on vacuous chewing movements, plasma glucose and oxidative stress indices in rats administered high dose risperidone.Scientific reports · 2022Article
- Effects of Cannabidiol on Locomotor Activity.Life (Basel, Switzerland) · 2022Review
- Cannabidiol (CBD) in Cancer Management.Cancers · 2022Review
- New Insights in the Involvement of the Endocannabinoid System and Natural Cannabinoids in Nicotine Dependence.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Fernanda F PeresInterdisciplinary Laboratory of Clinical Neurosciences, Department of Psychiatry, Federal University of São PauloSão Paulo, Brazil; Department of Pharmacology, Federal University of São PauloSão Paulo, Brazil.
Raquel LevinInterdisciplinary Laboratory of Clinical Neurosciences, Department of Psychiatry, Federal University of São PauloSão Paulo, Brazil; Department of Pharmacology, Federal University of São PauloSão Paulo, Brazil.
Mayra A SuiamaInterdisciplinary Laboratory of Clinical Neurosciences, Department of Psychiatry, Federal University of São PauloSão Paulo, Brazil; Department of Pharmacology, Federal University of São PauloSão Paulo, Brazil.
Mariana C DianaInterdisciplinary Laboratory of Clinical Neurosciences, Department of Psychiatry, Federal University of São PauloSão Paulo, Brazil; Department of Pharmacology, Federal University of São PauloSão Paulo, Brazil.
Douglas A GouvêaInterdisciplinary Laboratory of Clinical Neurosciences, Department of Psychiatry, Federal University of São PauloSão Paulo, Brazil; Department of Pharmacology, Federal University of São PauloSão Paulo, Brazil.
Valéria AlmeidaInterdisciplinary Laboratory of Clinical Neurosciences, Department of Psychiatry, Federal University of São PauloSão Paulo, Brazil; Department of Pharmacology, Federal University of São PauloSão Paulo, Brazil.
Camila M SantosInterdisciplinary Laboratory of Clinical Neurosciences, Department of Psychiatry, Federal University of São PauloSão Paulo, Brazil; Department of Pharmacology, Federal University of São PauloSão Paulo, Brazil.
Lisandro LungatoDepartment of Psychobiology, Federal University of São Paulo São Paulo, Brazil.
Antônio W ZuardiDepartment of Neuroscience and Behavior, University of São PauloRibeirão Preto, Brazil; National Institute for Translational Medicine - National Council for Scientific and Technological DevelopmentRibeirão Preto, Brazil.
Jaime E C HallakDepartment of Neuroscience and Behavior, University of São PauloRibeirão Preto, Brazil; National Institute for Translational Medicine - National Council for Scientific and Technological DevelopmentRibeirão Preto, Brazil.
José A CrippaDepartment of Neuroscience and Behavior, University of São PauloRibeirão Preto, Brazil; National Institute for Translational Medicine - National Council for Scientific and Technological DevelopmentRibeirão Preto, Brazil.
D'Almeida VâniaDepartment of Psychobiology, Federal University of São Paulo São Paulo, Brazil.
Regina H SilvaDepartment of Pharmacology, Federal University of São Paulo São Paulo, Brazil.
Vanessa C AbílioInterdisciplinary Laboratory of Clinical Neurosciences, Department of Psychiatry, Federal University of São PauloSão Paulo, Brazil; Department of Pharmacology, Federal University of São PauloSão Paulo, Brazil.
Universidade Federal de São Paulo · BRUniversidade de São Paulo · BRNational Council for Scientific and Technological Development · BR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabidiol (CBD) is a non-psychotomimetic compound from
Indexed as
cannabidiolParkinson’s diseaseratreserpineschizophreniatardive dyskinesia
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.